HLA-E and lymphoma: Treatment with IPH2201 has been shown to trigger NKG2A+ NK cell-mediated lysis of HLA-E+ target cells in vitro and abolish HLA-E+ leukemia and lymphoma tumors in xenograft mouse models of human neoplastic disease (NOD-SCID mice injected with HLA-E+ Epstein-Barr virus-positive cells or acute myeloid leukemia cells) (38).